WHO: Pandemic flu vaccine production to fall short

Sep 18, 2009
In this photo made on Friday, Sept. 11, 2009, Safety and security specialist for the Bayer Corporation U.S. headquarters, Thomas Barclay, right, receives an inoculation for influenza from company physicians assistant Tim Grimes, in the Pittsburgh suburb Robinson, Pa. The initial doses of the new swine flu vaccine will only be given to young people, pregnant women and other high-risk groups. Businesses will have to wait until those folks have been immunized to get swine flu vaccine for their workforce. Unless they jump through lots of hoops that vary from state by state to get it, creating confusion for companies, like Bayer, with offices all over the country. (AP Photo/Keith Srakocic)

(AP) -- Global production of swine flu vaccines will be "substantially less" than the previous maximum forecast of 94 million doses a week, the World Health Organization said Friday.

The number of doses produced in a year will therefore fall short of the 4.9 billion doses the global health body previously hoped could be available for the pandemic, WHO spokesman Gregory Hartl told reporters in Geneva.

Production will be lower because some manufacturers are still turning out vaccines for seasonal flu - an illness that can be serious in sick and elderly people, Hartl said.

Production problems also have reduced the weekly output of pandemic vaccine, he said.

The , France, Britain and six other countries announced Thursday that they will share part of their vaccine supply with poorer countries.

WHO welcomed the move Friday, saying it "demonstrates the commitment of these countries to fairness in sharing of scare resources."

"Current supplies of pandemic vaccine are inadequate for a world population in which virtually everyone is susceptible to infection by a new and readily contagious virus," it said.

WHO says that in theory all the world's 6.3 billion people should receive at least one dose of against the strain of H1N1 - also known as swine flu - to ensure comprehensive protection against the disease, which has so far killed some 3,500 people.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Bristol-Myers: FDA blocks hepatitis C drug for now

add to favorites email to friend print save as pdf

Related Stories

GlaxoSmithKline taking pandemic vaccine orders

May 15, 2009

(AP) -- Pharmaceutical giant GlaxoSmithKline said Friday it has received orders from several countries to stockpile pandemic vaccine as soon as it gets the vaccine's key ingredient from the World Health Organization.

WHO meets on production of swine flu vaccine

May 14, 2009

(AP) -- As swine flu cases hit 6,500 worldwide, World Health Organization officials were meeting with vaccine manufacturers and other experts in Geneva on Thursday to discuss making a vaccine to fight the virus.

Glaxo offers WHO 50 million pandemic vaccines

May 19, 2009

(AP) -- Drug giant GlaxoSmithKline said it has offered to donate 50 million doses of a pandemic vaccine to the World Health Organization in the event of a global flu outbreak, according to a company spokesman.

WHO: No swine flu vaccine available for months (Update)

May 19, 2009

(AP) -- Drug manufacturers won't be able to start making a swine flu vaccine until mid-July at the earliest, weeks later than previous predictions, the World Health Organization said Tuesday. It will then ...

WHO predicts 'explosion' of swine flu cases

Aug 21, 2009

(AP) -- The global spread of swine flu will endanger more lives as it speeds up in coming months and governments must boost preparations for a swift response, the World Health Organization said Friday.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.